Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "Europe At-home Respiratory Care Services Market Size, Share & Trends Analysis Report by Therapy (Oxygen Therapy, Non-Invasive Ventilation), by Indication ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness.

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

Newman University experts identify key qualities of exceptional respiratory therapists: technical skills, calm under pressure, empathy, and communication—essential traits in this growing field ...

May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...

My husband is considering contesting his brother’s will. Around 30 days before passing, his brother changed everything to go to a friend. He was in and out of the hospital the last few months of his ...

United Therapeutics UTHR remains poised to expand Tyvaso’s label in the respiratory disease space. It recently unveiled results from the late-stage TETON-2 study, which showed clinical benefit in ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present two oral ...